Abstract This review aims to address significant anomalies and discrepancies that have surfaced from the examination of the data from the Pfizer/BioNTech C4591001 trial, which could have profound implications for public trust and regulatory standards, should they not be adequately and transparently investigated. Whistleblower Testimonies Brook Jackson, a former […]
Report 76: Pfizer Had Data to Announce Its COVID-19 Vaccine’s Alleged “Efficacy” in October 2020. Why Did Pfizer Delay the Announcement Until November 9, 2020, Six Days After the 2020 U.S. Presidential Election?
Executive summary On July 21, 2020, the United States (U.S.) government, Pfizer, and BioNTech signed a contract, known as a Statement of Work (SOW), for the rapid development of and obtaining regulatory licensure for a COVID-19 vaccine by October 31, 2020, a few days prior to the November 3, 2020, […]
“170 Patients That Changed Everything” – Spectator | Australia
Few people realise that the Emergency Use Authorisation (EUA) of the Pfizer-BioNTech Covid-19 Vaccine/BNT162b2 was granted on the efficacy data of 170 patients. The 162 who received a placebo and 8 patients who were vaccinated formed the basis of the 95 per cent efficacy claims. There has not been much […]
Report 42: Pfizer’s EUA Granted Based on Fewer Than 0.4% of Clinical Trial Participants. FDA Ignored Disqualifying Protocol Deviations to Grant EUA.
Locations of the 170 Pfizer Clinical Trial Patients Used to Gain Emergency Use Authorization (EUA) for Its COVID mRNA Vaccine. Courtesy of OPENVAET.org For audio-visual explanations of this report, please see these videos. So much has been written about the pivotal Pfizer Trial for COVID-19 (C4591001), that it is sometimes […]